10 Things Worth Pay...
Health Care: Drugs
Cytokinetics Inc. (CYTK: NASDAQ)
$0.88 -0.02 | -2.17%
06/04/12 - 03:59 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.67 | 0.58 | 0.98 |
| Price to Sales (TTM) | 13.79 | 4.62 | 1.42 |
| Price to Book (MRQ) | 1.66 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 1.66 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -1.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -1.70 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 138.50 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 55.20 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -14.98 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -39.52 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 9.70 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 10.10 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -221.89 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -9.11 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -99.00 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -35.80 | 2.20 | 2.50 |
| Return on Investment (TTM) | -109.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -47.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 64,013.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -583,253.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 86.40 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.10 | 0.40 | 0.40 |
Portfolios with CYTK
- Portfolio NameUser Type
- Contributor$5 Stocks That Analysts Exp...
- UserBlue OAK
- UserDaveofDuke1111
- UserASCO 2010 Part 2
- ContributorBarron's Insider Purchases ...
- UserASCO 2009 Nymph's Watch List.
- UserHot Biotech Stocks II
- UserLet's Go Channeling
- UserDizziMage's Port
- Usermileslb Fidelity IRA
Latest CYTK Headlines from TheStreet
- Cytokinetics CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 11:10 pm
- $5 Stocks That Analysts Expect to Double 08.02.10 | 06:08 am
- Cytokinetics Inc. Q2 2010 Earnings Call Transcript 07.29.10 | 03:07 am
- Cytokinetics Ends Cancer Deal With GlaxoSmithKline 12.09.09 | 04:12 pm
- Movers Roundup: Manitowoc, Symantec 10.29.09 | 02:10 pm
- Cytokinetics Shares Fall On Drug Development Delay 10.29.09 | 12:10 pm
- Harmonic, SkyPeople: Midday Volume Plays 10.29.09 | 12:10 pm
- High Times
09.29.09 | 10:09 am - Cytokinetics: Pump Up The Volume 09.25.09 | 03:09 pm
- Optimer Soars on Antibiotic Data 11.11.08 | 12:11 pm
Press Releases for CYTK
Partner Headlines for CYTK
- Rodman & Renshaw Reiterates Cytokinetics Market Outperform, $4 PT - Benzinga 11.01.11 | 04:11 pm
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
- Cytokinetics Up 9% (CYTK) - Benzinga 04.12.11 | 09:04 am
- Cytokinetics: Most Recent Victim of Unjustified Biotech Sell-Off - Seeking Alpha 12.19.10 | 07:12 am
- UPDATE 1-Cytokinetics' Lou Gehrig's drug gets orphan status - Reuters 03.10.10 | 09:03 am
